Agilon Health price target raised to $30 from $21 at Guggenheim

Guggenheim analyst Sandy Draper raised the firm’s price target on Agilon Health to $30 from $21 and keeps a Buy rating on the shares. Agilon’s EBITDA guidance was the same as preliminary guidance in January, but the firm’s confidence, and investors’, has "greatly increased" as it relates to getting to the $580-$610M EBITDA target in 2026, while it appears that the company’s revenue growth is on track to exceed its 2026 targets, the analyst contends.